Alex TLC recently submitted evidence for the Scottish Medicine Consortium review of the medicine Libmeldy for approval of it through NHS Scotland for patients with metachromatic leukodystrophy (MLD).
Our submission provided information about how people are affected by MLD and the beneficial impact of Libmeldy on patients, their carers, and family.
We also participated in the Patient and Clinician Engagement (PACE) meeting discussing the benefits of Libmeldy including how it can impact the quality of a patient’s life.
